高盛发表报告指,科伦博泰(06990.HK) 公布靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT,亦称SKB264/MK-2870),联合默沙东的抗PD-1单抗“可瑞达”,一线治疗PD-L1阴性的局部晚期或转移性NSCLC的三期临床研究(OptiTROP-Lung06)已达到主要终点。该行预期,临床研究的正面结果为sac-TMT在治疗1L NSCLC...
Source Link高盛发表报告指,科伦博泰(06990.HK) 公布靶向人滋养细胞表面抗原2(TROP2)的抗体偶联药物(ADC)芦康沙妥珠单抗(sac-TMT,亦称SKB264/MK-2870),联合默沙东的抗PD-1单抗“可瑞达”,一线治疗PD-L1阴性的局部晚期或转移性NSCLC的三期临床研究(OptiTROP-Lung06)已达到主要终点。该行预期,临床研究的正面结果为sac-TMT在治疗1L NSCLC...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.